SCHEMBL14729023

SCHEMBL14729023

O=C(OCC1CCC1)N1CCC(Oc2nc3ccc(C4CCN(S(=O)(=O)CCCCO)CC4)cc3s2)CC1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 3/20 0.34
ACACB O00763 2/20 0.34
PDE4B Q07343 3/20 0.33
TLR9 Q9NR96 3/20 0.33
TLR8 Q9NR97 3/20 0.33
TLR7 Q9NYK1 3/20 0.33
NAMPT P43490 1/20 0.32
KDM4E B2RXH2 2/20 0.32
ALDH1A1 P00352 1/20 0.32
CYP2D6 P10635 1/20 0.32
CYP2C9 P11712 1/20 0.32
HPGD P15428 1/20 0.32
CYP2C19 P33261 1/20 0.32
MEN1 O00255 2/20 0.31
KMT2A Q03164 2/20 0.31
PKM P14618 1/20 0.31
NPC1 O15118 1/20 0.31
NPBWR1 P48145 1/20 0.31
RAB9A P51151 1/20 0.31
MCHR1 Q99705 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14729022 0.98 GPR119 (0.36) GPR119ACACBPDE4BTLR9TLR8
SCHEMBL14729021 0.90 GPR119 (0.36) GPR119ACACBPDE4BTLR9TLR8
SCHEMBL14729019 0.88 ACACB (0.36) GPR119ACACBPDE4BTLR9TLR8
SCHEMBL14729017 0.88 GPR119 (0.36) GPR119ACACBKDM4EALDH1A1CYP2D6
SCHEMBL14729013 0.85 GPR119 (0.38) GPR119ACACBKDM4EALDH1A1CYP2D6
SCHEMBL14729153 0.84 TLR9 (0.39) GPR119ACACBPDE4BTLR9TLR8
SCHEMBL14728960 0.84 FAAH (0.38) PDE4BNAMPTKDM4EALDH1A1HPGD
SCHEMBL14729016 0.83 GPR119 (0.40) GPR119ACACBENPP2
SCHEMBL14729014 0.81 GPR119 (0.40) GPR119ACACBENPP2
SCHEMBL14728924 0.81 DRD2 (0.42) ALDH1A1CYP2C9HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8940716-B2 Bicyclic heteroaryl compounds as GPR119 modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2015-01-27 US disclosed
US-8940716-B2 Bicyclic heteroaryl compounds as GPR119 modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2015-01-27 US disclosed
EP-2566860-B1 BICYCLIC HETEROARYL COMPOUNDS AS GPR119 MODULATORS BRISTOL MYERS SQUIBB CO (US) 2014-09-10 EP disclosed
US-20130053345-A1 BICYCLIC HETEROARLY ANALOGUES AS GPR119 MODULATORS BRISTOL-MYERS SQUIBB COMPANY 2013-02-28 US disclosed
US-20130053345-A1 BICYCLIC HETEROARLY ANALOGUES AS GPR119 MODULATORS BRISTOL-MYERS SQUIBB COMPANY 2013-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130053345-A1 BICYCLIC HETEROARLY ANALOGUES AS GPR119 MODULATORS GPR119, GPR139, GPR4 GPR119 1/4885ACACB 4238/4885PDE4B 556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.